Hoa Kỳ - Tiếng Anh - NLM (National Library of Medicine)

american health packaging - esomeprazole magnesium (unii: r6dxu4way9) (esomeprazole - unii:n3pa6559ft) - esomeprazole 20 mg - healing of erosive esophagitis esomeprazole magnesium delayed-release capsules are indicated for the short-term treatment (4 to 8 weeks) in the healing and symptomatic resolution of diagnostically confirmed erosive esophagitis. for those patients who have not healed after 4 to 8 weeks of treatment, an additional 4 to 8 week course of esomeprazole magnesium delayed-release capsules may be considered. in infants 1 month to less than 1 year, esomeprazole magnesium delayed-release capsules are indicated for short-term treatment (up to 6 weeks) of erosive esophagitis due to acid-mediated gerd. maintenance of healing of erosive esophagitis esomeprazole magnesium delayed-release capsules are indicated to maintain symptom resolution and healing of erosive esophagitis. controlled studies do not extend beyond 6 months. symptomatic gastroesophageal reflux disease esomeprazole magnesium delayed-release capsules are indicated for short-term treatment (4 to 8 weeks) of heartburn and other symptoms associated with

New Zealand - Tiếng Anh - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - omeprazole 20mg;  ; omeprazole 20mg - modified release capsule - 20 mg - active: omeprazole 20mg   excipient: dibasic sodium phosphate gelatin   hypromellose black ink   macrogol 6000 mannitol methacrylic acid - ethyl acrylate copolymer polysorbate 80 purified talc sodium laurilsulfate sugar spheres titanium dioxide     water   active: omeprazole 20mg excipient: dibasic sodium phosphate gelatin   hypromellose macrogol 6000 mannitol methacrylic acid - ethyl acrylate copolymer polysorbate 80 purified talc sodium laurilsulfate sugar spheres titanium dioxide     water   - omeprazole actavis capsules are indicated for the treatment of: · reflux oesophagitis · duodenal ulcer · gastric ulcer · nsaid-associated gastric and duodenal ulcers or erosions · symptoms of acid related dyspepsia · zollinger-ellison syndrome in the treatment of peptic ulceration, the eradication of h.pylori, as the causative organism, must be a high priority. accordingly, omeprazole actavis should be used as part of combination therapy for the eradication of h.pylori. omeprazole actavis capsules are indicated for maintenance treatment of: · reflux oesophagitis · duodenal ulcer · gastric ulcer · zollinger-ellison syndrome

Hoa Kỳ - Tiếng Anh - NLM (National Library of Medicine)

clinical solutions wholesale - omeprazole (unii: kg60484qx9) (omeprazole - unii:kg60484qx9) - omeprazole 20 mg - omeprazole delayed-release capsules are indicated for short-term treatment of active duodenal ulcer in adults. most patients heal within four weeks. some patients may require an additional four weeks of therapy. omeprazole delayed-release capsules, in combination with clarithromycin and amoxicillin, are indicated for treatment of patients with h. pylori infection and duodenal ulcer disease (active or up to 1-year history) to eradicate h. pylori in adults. omeprazole delayed-release capsules, in combination with clarithromycin are indicated for treatment of patients with h. pylori infection and duodenal ulcer disease to eradicate

Canada - Tiếng Anh - Health Canada

pharmascience inc - esomeprazole (esomeprazole magnesium dihydrate) - capsule (delayed release) - 20mg - esomeprazole (esomeprazole magnesium dihydrate) 20mg - proton-pump inhibitors

Canada - Tiếng Anh - Health Canada

teva canada limited - esomeprazole (esomeprazole magnesium dihydrate) - tablet (delayed-release) - 20mg - esomeprazole (esomeprazole magnesium dihydrate) 20mg - proton-pump inhibitors

Úc - Tiếng Anh - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - esomeprazole magnesium, quantity: 41.4 mg (equivalent: esomeprazole, qty 40 mg) - tablet, enteric coated - excipient ingredients: diethyl phthalate; sodium stearylfumarate; macrogol 400; macrogol 4000; macrogol 6000; crospovidone; purified talc; povidone; microcrystalline cellulose; hypromellose phthalate; hyprolose; titanium dioxide; hypromellose; iron oxide red; maize starch; sucrose - gastro-oesophageal reflux disease (gord),- treatment of erosive reflux oesophagitis,- long-term management of patients with healed oesophagitis to prevent relapse,- symptomatic treatment of gastro-oesophageal reflux disease (gord),patients requiring nsaid therapy,- short-term treatment of upper gastrointestinal symptoms associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy,- healing of gastric ulcers associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy,- prevention of gastric and duodenal ulcers associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy in patients at risk,prevention of rebleeding of gastric or duodenal ulcers following treatment with esomeprazole solution administered by intravenous infusion,pathological hypersecretory conditions including zollinger-ellison syndrome and idiopathic hypersecretion,in combination with appropriate antibiotics for:,- healing of duodenal ulcer associated with helicobacter pylori,- eradication of helicobacter pylori in patients with active or healed peptic ulcer

Hoa Kỳ - Tiếng Anh - NLM (National Library of Medicine)

golden state medical supply, inc. - omeprazole (unii: kg60484qx9) (omeprazole - unii:kg60484qx9) - omeprazole 40 mg - omeprazole delayed-release capsules are indicated for short-term treatment of active duodenal ulcer in adults. most patients heal within four weeks. some patients may require an additional four weeks of therapy. eradication of h. pylori has been shown to reduce the risk of duodenal ulcer recurrence. triple therapy omeprazole delayed-release capsules in combination with clarithromycin and amoxicillin, is indicated for treatment of patients with h. pylori infection and duodenal ulcer disease (active or up to 1-year history) to eradicate h. pylori in adults. dual therapy omeprazole delayed-release capsules in combination with clarithromycin is indicated for treatment of patients with h. pylori infection and duodenal ulcer disease to eradicate h. pylori in adults. among patients who fail therapy, omeprazole delayed-release capsules with clarithromycin are more likely to be associated with the development of clarithromycin resistance as compared with triple therapy. in patients who fail therapy, susce

Hoa Kỳ - Tiếng Anh - NLM (National Library of Medicine)

teva pharmaceuticals usa, inc. - omeprazole (unii: kg60484qx9) (omeprazole - unii:kg60484qx9) - omeprazole 40 mg - omeprazole delayed-release capsules are indicated for short-term treatment of active duodenal ulcer in adults. most patients heal within four weeks. some patients may require an additional four weeks of therapy. eradication of h. pylori has been shown to reduce the risk of duodenal ulcer recurrence. triple therapy omeprazole delayed-release capsules in combination with clarithromycin and amoxicillin, are indicated for treatment of patients with h. pylori infection and duodenal ulcer disease (active or up to 1-year history) to eradicate h. pylori in adults. dual therapy omeprazole delayed-release capsules in combination with clarithromycin are indicated for treatment of patients with h. pylori infection and duodenal ulcer disease to eradicate h. pylori in adults. among patients who fail therapy, omeprazole delayed-release capsules with clarithromycin are more likely to be associated with the development of clarithromycin resistance as compared with triple therapy. in patients who fail therapy, susceptibil

Hoa Kỳ - Tiếng Anh - NLM (National Library of Medicine)

golden state medical supply, inc. - omeprazole (unii: kg60484qx9) (omeprazole - unii:kg60484qx9) - omeprazole 40 mg - omeprazole delayed-release capsules are indicated for short-term treatment of active duodenal ulcer in adults. most patients heal within four weeks. some patients may require an additional four weeks of therapy. eradication of h. pylori has been shown to reduce the risk of duodenal ulcer recurrence. triple therapy omeprazole delayed-release capsules in combination with clarithromycin and amoxicillin, are indicated for treatment of patients with h. pylori infection and duodenal ulcer disease (active or up to 1-year history) to eradicate h. pylori in adults. dual therapy omeprazole delayed-release capsules in combination with clarithromycin are indicated for treatment of patients with h. pylori infection and duodenal ulcer disease to eradicate h. pylori in adults. among patients who fail therapy, omeprazole delayed-release capsules with clarithromycin are more likely to be associated with the development of clarithromycin resistance as compared with triple therapy. in patients who fail therapy, susceptibil

Hoa Kỳ - Tiếng Anh - NLM (National Library of Medicine)

a-s medication solutions - omeprazole (unii: kg60484qx9) (omeprazole - unii:kg60484qx9) - omeprazole 20 mg - omeprazole delayed-release capsules are indicated for short-term treatment of active duodenal ulcer in adults. most patients heal within four weeks. some patients may require an additional four weeks of therapy. eradication of h. pylori has been shown to reduce the risk of duodenal ulcer recurrence. triple therapy omeprazole delayed-release capsules in combination with clarithromycin and amoxicillin, is indicated for treatment of patients with h. pylori infection and duodenal ulcer disease (active or up to 1-year history) to eradicate h. pylori in adults. dual therapy omeprazole delayed-release capsules in combination with clarithromycin are indicated for treatment of patients with h. pylori infection and duodenal ulcer disease to eradicate h. pylori in adults. among patients who fail therapy, omeprazole delayed-release capsules with clarithromycin is more likely to be associated with the development of clarithromycin resistance as compared with triple therapy. in patients who fail therapy, susceptibilit